<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709706</url>
  </required_header>
  <id_info>
    <org_study_id>208471</org_study_id>
    <nct_id>NCT03709706</nct_id>
  </id_info>
  <brief_title>Pilot Immunotherapy Study With Autologous T-cells Specific for NY-ESO-1/ LAGE-1a-positive Advanced NSCLC Either Alone or in Combination With Pembrolizumab</brief_title>
  <official_title>A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adoptive T-cell therapy (ACT) is a therapeutic approach that uses T lymphocytes of
      participants with cancer, obtained by leukapheresis with the aim of generating an anti-tumor
      T-cell immune response. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer
      testis antigen 2 (LAGE-1a) antigens are tumor-associated proteins that have been found in
      several tumor types. Clinical trials using ACT with T-cells directed against NY-ESO-1/LAGE-1a
      have shown objective responses in participants with cancer. Pembrolizumab is a monoclonal
      antibody that acts specifically on tumor targeting T-cells and increases T-cell anti-tumor
      function. Pembrolizumab will be used in combination with NY-ESO-1/LAGE-1a T Cell Receptors
      (TCR) engineered participant T-cells (GSK3377794) to potentially further improve therapy for
      participants. The primary objective of the study is to evaluate the safety and tolerability
      of autologous genetically modified T-cells (GSK3377794) in human leukocyte antigen (HLA)
      positive participants with NY-ES0-1/ LAGE-1a positive advanced non-small cell lung cancer
      (NSCLC) alone (Arm A) or GSK3377794 in combination with pembrolizumab in participants with
      NSCLC with wildtype epidermal growth factor receptor (WT EGFR) and WT anaplastic lymphoma
      kinase/ c-ros oncogene 1 (ALK/ROS1) (Arm B) and participants with NSCLC with EGFR or ALK/ROS1
      aberration (Arm C). This study consists of screening phase, Leukapheresis/ GSK3377794
      manufacture, lymphodepletion/treatment phase and follow-up. Participants will receive
      GSK3377794 as monotherapy (Arm A); or as a combination therapy with pembrolizumab (Arm B),
      and participants in Arm C will receive the same treatment as participants in the Arm B.
      Approximately 54 participants will be enrolled into the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will receive either a single intravenous (IV) infusion of GSK3377794 as monotherapy or as combination therapy along with pembrolizumab IV infusion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study. Hence, there will be no masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) in participants who received GSK3377794 alone or in combination with pembrolizumab</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events of different severity in participants who received GSK3377794 alone or in combination with pembrolizumab</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>The severity of AEs will be graded according to National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with AEs and SAEs leading to dose delays</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Number of participants with AEs and SAEs leading to dose delays will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with AEs and SAEs leading to withdrawals</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Number of participants with AEs and SAEs leading to withdrawals will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal findings for hematology parameters</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Blood samples will be collected for analysis of hematology parameters including platelet counts, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, red blood cell count (RBC), hemoglobin and hematocrit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal findings for clinical chemistry parameters</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Blood samples will be collected for analysis of clinical chemistry parameters including blood urea nitrogen (BUN), potassium, aspartate aminotransferase (AST), total and direct bilirubin, creatinine, sodium, alanine aminotransferase (ALT), total protein, glucose, calcium, alkaline phosphatase, chloride, albumin, phosphorus, low density lipid (LDH), urea, potassium, magnesium and bicarbonate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal findings for urinalysis parameters</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Urine samples will be collected for the analysis of the following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite and leukocyte esterase by dipstick.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of of participants with abnormal findings for vital signs</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Vital sign parameters including systolic and diastolic blood pressure, respiratory rate, pulse rate, and temperature will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Eastern Cooperative Oncology Group (ECOG) performance status score</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>ECOG performance status is a measure of the participant's ability to carry out activities of daily living on a 6-point scale ranging from 0 (fully active) to 5 (Dead).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal electrocardiogram (ECG) findings</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>Twelve-lead ECG will be obtained using an ECG machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>ORR is the percentage of participants with a confirmed complete response (CR) or a partial response (PR) at any time as per Response evaluation criteria in solid tumors (RECIST) version 1.1 as determined by the local investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>PFS is defined as the time from the date of T-cell infusion until the earliest date of disease progression as per RECIST version 1.1 as determined by the local investigators, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>DCR is defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD) for at least 6 months as per RECIST version 1.1 as determined by the local investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>DoR is defined as, in the subset of participants who show a confirmed CR or PR as determined by the local investigators, the time from first documented evidence of CR or PR until the first documented sign of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 106 weeks</time_frame>
    <description>TTR is the time from the date of T-cell infusion to the first documented evidence of response (PR or better) in the subset of participants who achieved a confirmed PR or CR as determined by the local investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) following administration of monotherapy of GSK3377794</measure>
    <time_frame>Up to 106 weeks post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax following administration of combination therapy of GSK3377794</measure>
    <time_frame>Up to 106 weeks post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) following administration of monotherapy of GSK3377794</measure>
    <time_frame>Up to 106 weeks post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax following administration of combination therapy of GSK3377794</measure>
    <time_frame>Up to 106 weeks post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time curve from zero to time t (AUC[0 to t]) following administration of monotherapy of GSK3377794</measure>
    <time_frame>Up to 106 weeks post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0 to t) following administration of combination therapy of GSK3377794</measure>
    <time_frame>Up to 106 weeks post-dose</time_frame>
    <description>Blood samples will be collected for pharmacokinetic analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A: Participants receiving GSK3377794 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm A, participants will receive GSK3377794 monotherapy, administered as a single IV infusion of 1 to 8 x10^9 transduced cells. Participants who subsequently progress by Week 25 will be offered pembrolizumab 200 milligrams once every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Participants receiving GSK3377794 plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm B, participants will receive a single IV infusion of GSK3377794 on Day 1 followed by pembrolizumab 200 milligrams on Day 22 and thereafter once every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Participants receiving GSK3377794 with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Arm C, participants will receive a single IV infusion of GSK3377794 on Day 1 followed by pembrolizumab 200 milligrams on Day 22 and thereafter once every three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3377794</intervention_name>
    <description>GSK3377794 will be given as a single IV infusion of 1 to 8 x10^9 transduced cells.</description>
    <arm_group_label>Arm A: Participants receiving GSK3377794 monotherapy</arm_group_label>
    <arm_group_label>Arm B: Participants receiving GSK3377794 plus pembrolizumab</arm_group_label>
    <arm_group_label>Arm C: Participants receiving GSK3377794 with pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be given as a dose of 200 milligrams using a 30-minute IV infusion.</description>
    <arm_group_label>Arm B: Participants receiving GSK3377794 plus pembrolizumab</arm_group_label>
    <arm_group_label>Arm C: Participants receiving GSK3377794 with pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Screening (Part 1):

          -  The participant (or legally acceptable representative if applicable) provides written
             informed consent for the trial.

          -  Participant must be positive for Human leukocyte antigen (HLA)-A*02:01, HLA-A*02:05,
             and/or HLA-A*02:06 alleles by a validated test in a designated central laboratory.

          -  Participant's tumor has been pathologically reviewed by a designated central
             laboratory with confirmed positive expression of NY-ESO-1 and/or, if tested, LAGE-1a.

          -  Age &gt;=18 years on the day of signing informed consent for the screening process.

          -  Pending approval of Medical Monitor (or designee), participants can be enrolled in
             other experimental interventional clinical studies during the screening and
             leukapheresis stages of this study (GSK208471).

          -  Histologically or cytologically diagnosed unresectable Stage IIIb or Stage IV NSCLC.

          -  ECOG Performance Status of 0 or 1.

          -  Predicted life expectancy that is &gt;=3 months.

          -  Participant has left ventricular ejection fraction &gt;=50 percent (%) or as per
             institution's guidelines.

          -  Adequate venous access for leukapheresis.

          -  In the Investigator's opinion, the participant is fit for lymphodepleting chemotherapy
             and infusion of GSK3377794.

        Leukapheresis (Part 2):

          -  In the Investigator's opinion, the participant is suitable for leukapheresis including
             laboratory parameters as described in the protocol.

          -  Leukapheresis can be collected between the lines of therapies

          -  An intermediate standard of care (SoC) line of therapy between leukapheresis (Part 2)
             and treatment (Part 3) at the time of disease progression is allowed.

        Lymphodepletion/Treatment (Part 3):

          -  All participants with NSCLC with WT EGFR and WT ALK/ ROS1 (Arms A and B) should have
             received and failed at least one line of programmed death protein 1/programmed death
             protein 1 ligand (PD-1/PD-L1) checkpoint blockade therapy (alone or in combination
             with systemic chemotherapy).

          -  All participants with NSCLC with EGFR or ALK/ROS1 aberration (Arm C only) should have
             received and failed appropriate targeted therapy following National Comprehensive
             Cancer Network (NCCN) guidelines. These participants could have received and failed
             PD-1/PD-L1 checkpoint blockade therapy.

          -  Experimental systemic regimens are allowed.

          -  Histologically or cytologically diagnosed unresectable Stage IIIb or Stage IV NSCLC
             with measurable disease per RECIST version 1.1 as assessed by local site
             investigator/radiology.

          -  Central nervous system (CNS) metastases with low CNS disease burden are allowed on a
             case by case basis after benefit-risk evaluation in consultation with the Sponsor
             Medical Monitor (or designee).

          -  A biopsy of tumor tissue obtained following cessation of the last line of treatment
             for NSCLC but within 2 weeks prior to initiating lymphodepleting chemotherapy is
             required unless clinically unsafe to do so.

          -  Contraceptive use by men or women should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies.

          -  A female participants are eligible to participate if they are not pregnant or
             breastfeeding and if she is not of childbearing potential.

          -  Participant must have adequate organ function as described in the protocol.

        Pembrolizumab therapy following disease progression after GSK3377794 infusion (Arm A only,
        Part 4):

          -  Participants who have received GSK3377794 in Arm A are eligible for therapy with
             pembrolizumab 200 milligrams flat dose once every 3 weeks if they fulfil certain
             criteria.

        Exclusion Criteria:

        For Screening (Part 1):

          -  NSCLC with B-Raf gene (BRAF) V600E mutation, Neurotrophic Tropomyosin-Related Kinase
             (NTRK) gene fusion, and/or any other actionable genetic aberration that can be treated
             with targeted SoC (NCCN recommended) therapy.

          -  Prior therapies: Arm A and B: Has received and failed &gt;=3 lines of systemic therapy.
             Arm C: Has received &gt;=4 lines of systemic therapy.

          -  Any prior treatment with oncology cell therapy (TCR-T-cell therapy or chimeric antigen
             receptor [CAR]-T therapy); Prior gene therapy using an integrating vector.

          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression.

          -  Prior malignancy other than NSCLC, with exceptions: agreed upon consultation between
             the Investigator and Sponsor Medical Monitor (or designee).

          -  Participant has an active autoimmune disease that has required systemic treatment in
             past 2 years.

          -  Participant has a history of chronic or recurrent (within the last year prior to
             enrollment) severe autoimmune or active immune-mediated disease requiring steroids or
             other immunosuppressive treatments.

          -  Prior allogeneic/autologous bone marrow or solid organ transplantation with some
             exceptions if occurred more than 5 years ago.

          -  Uncontrolled intercurrent illness.

          -  Prior or active demyelinating disease.

          -  Current unstable liver or biliary disease per Investigator assessment.

          -  Participant has positive viral serology as defined in protocol.

          -  Participant is pregnant or breastfeeding.

          -  Has known psychiatric or substance abuse disorders.

        Leukapheresis (Part 2):

          -  Toxicity from previous anti-cancer therapy that has not recovered to CTCAE version
             4.03 Grade &lt;=1 prior to enrollment (except for non-clinically significant toxicities,
             e.g.,alopecia, vitiligo). Participants with existing pneumonitis because of radiation
             are not excluded; however, participants cannot be oxygen-dependent. Participants with
             Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral
             neuropathy) can be enrolled on a case-by-case basis with prior consultation and
             agreement with the Sponsor Medical Monitor (or designee).

          -  Investigational treatment within 30 days or 5 half-lives (whichever is shorter) prior
             to leukapheresis.

          -  Radiotherapy that involves &gt;25% bone marrow exposure.

        Lymphodepletion/ Treatment (Part 3):

          -  Has received a live vaccine within 30 days prior to the first dose of study drug.

          -  Major surgery &lt;=28 days before first dose of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erminia Massarelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0987</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sandip P Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Riess</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joel W Neal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Falchook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gilberto Lopes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Taofeek Kunle Owonikoko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Everett Vokes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Villano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Rolfo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ramaswamy Govindan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marjorie G Zauderer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Clarke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kai He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martin J. Edelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Liza Villaruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melissa L Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mehmet Altan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wallace L Akerley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian Sacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Turcotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John B.A.G. Haanen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thijo J.N. Hiltermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martijn P.J.K. Lolkema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eelke H. Gort</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Enriqueta Felip</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Moreno García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Emiliano Calvo Aller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3377794</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>T Cell Receptors</keyword>
  <keyword>Adoptive T-cell therapy</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

